Regeneron's Eylea, Covid-19 Treatment Contribute to 4Q Sales Gains
05 February 2021 - 11:16PM
Dow Jones News
By Matt Grossman
Regeneron Pharmaceuticals Inc. Friday logged a stronger profit
and higher revenue in the latest quarter, fueled by growing sales
for the company's Eylea eye medication and a small revenue
contribution from the company's Covid-19 antibody cocktail.
The Tarrytown, N.Y.-based pharmaceutical company posted a profit
of $10.24 a share, compared with $6.93 a share in the same quarter
a year earlier. Its net income was $1.15 billion, up from $792
billion in the year-ago quarter
The company's adjusted profit was $9.53 a share. Analysts
surveyed by FactSet were expecting an adjusted profit of $8.38 a
share.
Revenue was $2.42 billion, a 30% increase from $1.86 billion in
the fourth quarter of 2019. Analysts had forecast revenue of $2.42
billion.
REGEN-COV, the company's antibody cocktail for Covid-19,
generated sales in the quarter of $146 million in the quarter,
contributing to sales of $186 million for the product during all of
2020. Regeneron's Eylea eye medication was responsible for $1.34
billion in sales, up from $1.22 billion in the year-ago
quarter.
Research and development costs grew 35% to $745 million.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
February 05, 2021 07:01 ET (12:01 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jul 2023 to Jul 2024